Efficacy and Baseline Predictors of Tofacitinib Response in Patients with Rheumatoid Arthritis at a Private Tertiary Care Hospital in Pakistan

Objective

To analyze the efficacy of Tofacitinib and predictors of response in Rheumatoid Arthritis patients Study Design: Prospective longitudinal study Place and Duration of Study: Rheumatology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan, from Mar to Sep 2024. Methodology: The study included 76 adult RA patients (75 females and 1 male), who were advised to take Tofacitinib. We recorded the DAS-28 ESR at baseline and after 3 months and noted patient demographics, BMI, serology, and concomitant DMARD use. The primary outcome was remission/low disease activity (DAS-28≤3.2) at 3 months. DAS-28 levels were compared by Wilcoxon test. Treatment outcome was categorized as a good response and poor response. Predictors of treatment response were analyzed using univariate logistic regression analysis.